SCHEMBL756431

SCHEMBL756431

C[C@@H]1C[C@@]2(CCN1)C(NC1CCCCC1)=NC(=O)N2c1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.41
ADORA2A P29274 3/20 0.41
ADORA1 P30542 3/20 0.41
BACE1 P56817 4/20 0.37
BACE2 Q9Y5Z0 1/20 0.36
FYN P06241 1/20 0.36
HCRTR1 O43613 1/20 0.35
ALOX5 P09917 1/20 0.35
LMNA P02545 1/20 0.34
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740840 1.00 ADORA3 (0.41) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL757208 1.00 ADORA3 (0.41) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL760114 1.00 ADORA3 (0.41) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL4787016 1.00 ADORA3 (0.41) ADORA3ADORA2AADORA1BACE1BACE2
Hydrochloric Acid SCHEMBL592557 0.89 ADORA3 (0.42) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL5616630 0.88 BACE1 (0.34) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL757211 0.88 BACE1 (0.34) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL759418 0.88 BACE1 (0.34) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL14640805 0.88 BACE1 (0.34) ADORA3ADORA2AADORA1BACE1BACE2
SCHEMBL10214603 0.88 BACE1 (0.34) ADORA3ADORA2AADORA1BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
EP-1910364-B1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
WO-2007011810-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease BACE1, APP, PSEN1 ADORA3 2669/4885ADORA2A 2702/4885ADORA1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.